This escalation will not be performed to find a toxic dose limit since TILs are autologous cells but rather to ensure that the combined treatment (TILs + IL-2 + nivolumab) does not cause severe autoimmunity pathologies, justifying lower doses than those commonly administered. The gene discussed is IL2; the disease is Autoimmunity.